Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes

Tirzepatide and injectable semaglutide had similar rates of major adverse liver outcomes over roughly 17 months in adults with overweight or obesity and type 2 diabetes. Tirzepatide was associated with a modestly greater BMI reduction. Both drugs outperformed sitagliptin in an internal validation analysis.

Journal article — Retrospective target trial emulation. Population: Adults with overweight or obesity and type 2 diabetes from the TriNetX global network. Follow-up: median follow-up ~17 months. Interventions: tirzepatide; injectable semaglutide.

Over a median follow-up of about 17 months, the estimated MALO incidence rate was 4.05 per 1000 person-years with tirzepatide and 4.04 per 1000 person-years with semaglutide, with no significant difference (HR 1.04, 95% CI 0.88-1.23). In people with MASLD, incidence rates were 9.97 vs 10.03 per 1000 person-years (HR 1.03, 95% CI 0.75-1.42). The as-treated analysis also showed no difference (HR 0.98, 95% CI 0.80-1.21). Tirzepatide was associated with a greater BMI reduction (mean difference ~1.1 kg/m2, p < 0.001). Both agents significantly outperformed sitagliptin in internal validation.

This paper provides real-world comparative evidence that tirzepatide and injectable semaglutide have similar short-to-medium term major adverse liver outcome risk in people with type 2 diabetes and overweight or obesity, while tirzepatide showed a modest BMI advantage. It does not establish long-term prevention of cirrhosis or hepatocellular carcinoma and does not assess liver histology or fibrosis. For researchers focused on Tirzepatide, it supports hepatic event risk comparable to semaglutide and may inform future liver-outcome studies.

Key findings

• No significant difference in major adverse liver outcome risk was seen between tirzepatide and semaglutide initiators (HR 1.04, 95% CI 0.88-1.23).
• Estimated incidence rates were 4.05 per 1000 person-years for tirzepatide and 4.04 per 1000 person-years for semaglutide.
• In people with MASLD, incidence rates were 9.97 vs 10.03 per 1000 person-years (HR 1.03, 95% CI 0.75-1.42).
• The as-treated analysis gave an HR of 0.98 (95% CI 0.80-1.21), also suggesting comparable risk.
• Tirzepatide achieved greater BMI reduction, with a mean difference of about 1.1 kg/m2 (p < 0.001).
• Both agents significantly outperformed sitagliptin in internal validation.

Limitations

• Retrospective observational design; residual confounding is possible despite propensity-score matching.
• Follow-up was short-to-medium term (~17 months), so longer-term liver outcomes were not captured.
• Reliance on electronic health-record coding may lead to outcome misclassification.
• No histologic or fibrosis data were reported; only clinical MALO events were assessed.

The record

• Journal: Obesity (Silver Spring, Md.)
• Published: 2026-08-19
• PMID: 42618523 — DOI: 10.1002/oby.70277
• Funding: Narayana Health
• Author countries: India, UK

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….